A 33% five-year survival rate is the stubborn ceiling AML has refused to budge past for years, and it frames exactly what Amphista Therapeutics is betting on with AMX-883 — a DCAF16-dependent BRD9 degrader that just cleared FDA’s IND review and is scheduled to enter the clinic in the second half of 2026. The mechanism is the point of departure: rather than recruiting cereblon or VHL to direct degradation, AMX-883 uses Amphista’s proprietary Targeted Glue™ chemistry to achieve near-complete BRD9 knockdown within two hours, while global proteomics data show selectivity is maintained across all other bromodomain-containing proteins. That preclinical selectivity profile is precisely what regulators and, eventually, clinical investigators will stress-test.
The Phase 1 design is a standard monotherapy dose-escalation and optimisation trial enrolling relapsed or refractory AML and high-risk myelodysplastic syndrome patients — a population that has already exhausted prior options. What makes the trial more than a routine safety run is the pre-specified combination roadmap. Once monotherapy pharmacokinetics and tolerability are established, Amphista intends to layer in venetoclax plus azacitidine in earlier lines, directly targeting the resistance dynamic that increasingly defines modern AML practice. Venetoclax-based combinations have become a backbone of frontline therapy, but acquired resistance is a documented and growing clinical problem. Preclinical data show AMX-883 acts synergistically with venetoclax in vivo and, critically, prevents the emergence of venetoclax resistance in vitro — a mechanistic claim that, if it translates, would move AMX-883 from salvage asset to potential combination anchor.
The competitive framing matters here. AML therapy has evolved meaningfully: oral azacitidine received FDA approval in 2020 for continued AML treatment, and revumenib earned full approval in October 2025 for NPM1-mutated relapsed or refractory AML. These are mutation-selective wins. AMX-883’s proposed differentiation is karyotype independence — BRD9 degradation removes the differentiation block regardless of genetic subtype, which theoretically opens a broader patient population than agents tied to specific mutations. That claim still has to survive contact with clinical heterogeneity.
The single number to track as the Phase 1 opens is the depth and durability of BRD9 degradation in peripheral blood or marrow blasts from the first dose-escalation cohorts. If the two-hour near-complete knockdown observed preclinically reproduces in patients at a tolerable dose, the combination expansion with venetoclax becomes a genuine clinical priority rather than an aspirational footnote in a press release.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
